Physician profile

Ching Wong

Hematology & Oncology · Brooklyn, NY

NPI 1821095233

$2,059.57

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$49.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $489.18 2019-2021
Glaxosmithkline, LLC. $375.00 2019-2022
Novo Nordisk INC $250.00 2019-2020
Merck Sharp & Dohme LLC $240.36 2019-2022
Gilead Sciences, INC. $185.00 2019
Astellas Pharma US INC $125.00 2019
Beigene USA, INC. $125.00 2021
E.R. Squibb & Sons, L.L.C. $120.19 2022
Incyte Corporation $99.95 2019
Novartis Pharmaceuticals Corporation $49.89 2023-2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ching Wong

$2,059.57

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals Lp

https://glasscript.com/doctor/354621/ching-wong

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.